Annual CFF
$33.65 M
+$32.53 M+2931.08%
December 31, 2023
Summary
- As of February 7, 2025, VYGR annual cash flow from financing activities is $33.65 million, with the most recent change of +$32.53 million (+2931.08%) on December 31, 2023.
- During the last 3 years, VYGR annual CFF has risen by +$30.48 million (+963.71%).
- VYGR annual CFF is now -81.07% below its all-time high of $177.74 million, reached on December 31, 2015.
Performance
VYGR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$14.00 K
-$557.00 K-97.55%
September 30, 2024
Summary
- As of February 7, 2025, VYGR quarterly cash flow from financing activities is $14.00 thousand, with the most recent change of -$557.00 thousand (-97.55%) on September 30, 2024.
- Over the past year, VYGR quarterly CFF has dropped by -$446.00 thousand (-96.96%).
- VYGR quarterly CFF is now -99.99% below its all-time high of $112.86 million, reached on March 31, 2024.
Performance
VYGR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$113.90 M
-$317.00 K-0.28%
September 30, 2024
Summary
- As of February 7, 2025, VYGR TTM cash flow from financing activities is $113.90 million, with the most recent change of -$317.00 thousand (-0.28%) on September 30, 2024.
- Over the past year, VYGR TTM CFF has increased by +$80.26 million (+238.54%).
- VYGR TTM CFF is now -35.92% below its all-time high of $177.74 million, reached on December 31, 2015.
Performance
VYGR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VYGR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2931.1% | -97.0% | +238.5% |
| 3 y3 years | +963.7% | -94.9% | +10000.0% |
| 5 y5 years | +608.5% | -94.9% | +10000.0% |
VYGR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +5397.6% | -100.0% | +16.7% | -1.1% | >+9999.0% |
| 5 y | 5-year | -58.5% | +5397.6% | -100.0% | -100.0% | -1.1% | >+9999.0% |
| alltime | all time | -81.1% | +6445.7% | -100.0% | +101.5% | -35.9% | >+9999.0% |
Voyager Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $14.00 K(-97.5%) | $113.90 M(-0.3%) |
| Jun 2024 | - | $571.00 K(-99.5%) | $114.22 M(-0.8%) |
| Mar 2024 | - | $112.86 M(>+9900.0%) | $115.19 M(+242.4%) |
| Dec 2023 | $33.65 M(+2931.1%) | $460.00 K(+39.0%) | $33.65 M(+0.5%) |
| Sep 2023 | - | $331.00 K(-78.6%) | $33.46 M(+1.0%) |
| Jun 2023 | - | $1.55 M(-95.1%) | $33.15 M(+2.3%) |
| Mar 2023 | - | $31.31 M(>+9900.0%) | $32.40 M(+2819.3%) |
| Dec 2022 | $1.11 M(+81.4%) | $276.00 K(+1740.0%) | $1.11 M(+4.6%) |
| Sep 2022 | - | $15.00 K(-98.1%) | $1.06 M(+1.4%) |
| Jun 2022 | - | $807.00 K(+6625.0%) | $1.05 M(+75.5%) |
| Mar 2022 | - | $12.00 K(-94.7%) | $596.00 K(-2.6%) |
| Dec 2021 | $612.00 K(-80.7%) | $227.00 K(>+9900.0%) | $612.00 K(-29.7%) |
| Sep 2021 | - | $0.00(-100.0%) | $871.00 K(-36.9%) |
| Jun 2021 | - | $357.00 K(+1175.0%) | $1.38 M(-56.3%) |
| Mar 2021 | - | $28.00 K(-94.2%) | $3.16 M(-0.2%) |
| Dec 2020 | $3.16 M(-96.1%) | $486.00 K(-4.7%) | $3.16 M(+6.2%) |
| Sep 2020 | - | $510.00 K(-76.1%) | $2.98 M(-29.0%) |
| Jun 2020 | - | $2.13 M(+6173.5%) | $4.19 M(+34.0%) |
| Mar 2020 | - | $34.00 K(-88.7%) | $3.13 M(-96.1%) |
| Dec 2019 | $80.99 M | $300.00 K(-82.6%) | $80.99 M(-0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | $1.72 M(+61.3%) | $81.13 M(+0.4%) |
| Jun 2019 | - | $1.07 M(-98.6%) | $80.77 M(-0.1%) |
| Mar 2019 | - | $77.90 M(>+9900.0%) | $80.82 M(+1601.9%) |
| Dec 2018 | $4.75 M(-92.1%) | $435.00 K(-68.2%) | $4.75 M(-92.4%) |
| Sep 2018 | - | $1.37 M(+22.5%) | $62.58 M(+1.3%) |
| Jun 2018 | - | $1.12 M(-38.9%) | $61.77 M(+1.0%) |
| Mar 2018 | - | $1.83 M(-96.9%) | $61.15 M(+2.0%) |
| Dec 2017 | $59.92 M(>+9900.0%) | $58.26 M(>+9900.0%) | $59.92 M(+2860.5%) |
| Sep 2017 | - | $556.00 K(+11.6%) | $2.02 M(+33.1%) |
| Jun 2017 | - | $498.00 K(-17.3%) | $1.52 M(+36.8%) |
| Mar 2017 | - | $602.00 K(+63.6%) | $1.11 M(+116.3%) |
| Dec 2016 | $514.00 K(-99.7%) | $368.00 K(+594.3%) | $514.00 K(-99.3%) |
| Sep 2016 | - | $53.00 K(-40.4%) | $74.06 M(+1.4%) |
| Jun 2016 | - | $89.00 K(+2125.0%) | $73.05 M(-45.0%) |
| Mar 2016 | - | $4000.00(-100.0%) | $132.81 M(-25.3%) |
| Dec 2015 | $177.74 M(+703.5%) | $73.91 M(-7863.7%) | $177.74 M(+71.2%) |
| Sep 2015 | - | -$952.00 K(-101.6%) | $103.83 M(-0.9%) |
| Jun 2015 | - | $59.84 M(+33.2%) | $104.79 M(+133.2%) |
| Mar 2015 | - | $44.94 M | $44.94 M |
| Dec 2014 | $22.12 M | - | - |
FAQ
- What is Voyager Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Voyager Therapeutics?
- What is Voyager Therapeutics annual CFF year-on-year change?
- What is Voyager Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Voyager Therapeutics?
- What is Voyager Therapeutics quarterly CFF year-on-year change?
- What is Voyager Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Voyager Therapeutics?
- What is Voyager Therapeutics TTM CFF year-on-year change?
What is Voyager Therapeutics annual cash flow from financing activities?
The current annual CFF of VYGR is $33.65 M
What is the all time high annual CFF for Voyager Therapeutics?
Voyager Therapeutics all-time high annual cash flow from financing activities is $177.74 M
What is Voyager Therapeutics annual CFF year-on-year change?
Over the past year, VYGR annual cash flow from financing activities has changed by +$32.53 M (+2931.08%)
What is Voyager Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VYGR is $14.00 K
What is the all time high quarterly CFF for Voyager Therapeutics?
Voyager Therapeutics all-time high quarterly cash flow from financing activities is $112.86 M
What is Voyager Therapeutics quarterly CFF year-on-year change?
Over the past year, VYGR quarterly cash flow from financing activities has changed by -$446.00 K (-96.96%)
What is Voyager Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VYGR is $113.90 M
What is the all time high TTM CFF for Voyager Therapeutics?
Voyager Therapeutics all-time high TTM cash flow from financing activities is $177.74 M
What is Voyager Therapeutics TTM CFF year-on-year change?
Over the past year, VYGR TTM cash flow from financing activities has changed by +$80.26 M (+238.54%)